Table 5. Clinical significance of MIF genotype in patients with untreated Graves disease.

	rs755622 genotypes
Characteristic	G/G (n = 137)	G/C + C/C (n = 61)	P value
Female gender [n (%)]	104	53	0.138
	(75.9)	(85.2)
Age [year, median (range)]	37.0	42.0	0.027
	(17–77)	(22–74)
With cigarette smoking history [n (%)]	37	15	0.721
	(71.2)	(28.8)
With radioiodine treatment [n (%)]	3	2	0.652
	(2.2)	(3.3)
With thyroid gland surgery [n (%)]	3	5	0.047
	(2.2)	(8.2)
With ophthalmopathy [n (%)]	59	24	0.624
	(43.1)	(39.3)
With nodular hyperplasia [n (%)]	8	6	0.311
	(5.8)	(9.8)
With myxedema [n (%)]	0	1	0.133
	(0.0)	(1.6)
With vitiligo [n (%)]	0	2	0.033
	(0.0)	(3.3)
FT4 (ng/dL)[mean (SD)]	2.2	2.1	0.717
	(1.5)	(1.5)
TSH (mIU/L)[mean (SD)]	2.9	2.5	0.857
	(13.8)	(14.0)
TRAb (%)[mean (SD)]	52.0	49.0	0.588
	(24.3)	(23.6)

Abbreviations: MIF, macrophage migration inhibitory factor; FT4, free thyroxine; TSH, thyroid stimulating hormone; TRAb, anti-thyroid hormone receptor antibody; SD, standard deviation.